Biosimilar Antibodies: Empowering Faster Drug Discovery

The Critical Role of Biosimilar Antibodies in Modern Biotherapy

In the fast-paced world of biopharmaceutical research, accessing high-quality therapeutic antibodies for benchmarking is a common bottleneck. Traditional sourcing of commercial-grade drugs is often cost-prohibitive and restricted strictly for clinical use. To bridge this gap, CUSABIO has developed an extensive portfolio of research-grade biosimilar antibodies, designed to empower researchers with high-fidelity tools for competitive analysis and drug development.

What are Research-Grade Biosimilar Antibodies?

Biosimilar antibodies are recombinant tools designed to be highly similar in structure, function, and sequence to approved original therapeutic antibodies. By utilizing advanced mammalian expression systems, CUSABIO ensures that these antibodies retain the exact variable regions (Fv) of the original drugs. This makes them indispensable, cost-effective reagents for drug development and fundamental immunological research.

Why Choose CUSABIO Biosimilar Antibodies?

Unlike standard catalog antibodies, CUSABIO’s biosimilar antibodies are specifically optimized for sensitive functional assays. Key technical breakthroughs include:

• 100% Sequence Identity: Identical variable and Fc regions to approved therapeutic sequences (e.g., Ustekinumab, Zimberelimab).
• Low Endotoxin Levels: Essential for maintaining cell viability and preventing non-specific immune activation in in vitro and in vivo models.
• Azide-Free Formulation: Ensures no interference with biological activities during functional blocking or cell-based assays.
• Validated Binding Activity: Every batch is verified via ELISA, providing precise EC50 values to ensure experimental reproducibility.

Versatile Applications in the R&D Pipeline

CUSABIO’s biosimilar antibody collection (featuring over 200 targets) supports researchers at multiple stages of the R&D pipeline:

1. Mechanism of Action (MOA) Studies: Evaluate cytotoxicity (ADCC/CDC) and blocking effects with a reliable positive control.
2. Pharmacokinetics (PK) & Immunogenicity Assays: Use biosimilar antibodies as reference standards for developing ADA (Anti-Drug Antibody) assays.
3. Diagnostic Development: Serve as high-fidelity controls for Flow Cytometry and IHC, or for validating companion diagnostics.
4. Preclinical Efficacy: With specialized formulations, these antibodies can be directly administered in animal models for dose exploration.

Expanding the Research Horizon

The catalog includes recent breakthroughs and popular targets such as PD-1 (Zimberelimab Biosimilar), IL17A (Vunakizumab Biosimilar), and EGFR (ZZ-06 Biosimilar). Whether you are focusing on oncology, autoimmune diseases, or neurological markers, CUSABIO provides the scalable supply, from microliters to grams, needed to move your project from the bench to the clinic.

Explore the full catalog of CUSABIO Research-Grade Biosimilar Antibodies and streamline your critical research workflows today.